In four unblinded randomized studies, compared with placebo, somatostatin showed a trend toward benefit, with an overall risk reduction by 17% [ 6 ].
1
—
—
In four unblinded randomized studies, compared with placebo, somatostatin showed a trend toward benefit, with an overall risk reduction by 17% [ 6 ].